IntelliPharmaCeutics International Company Profile (TSE:I)

About IntelliPharmaCeutics International (TSE:I)

IntelliPharmaCeutics International logoIntellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: TSE:I
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: C$3.41
  • 200 Day Moving Avg: C$3.41
  • 52 Week Range: C$1.78 - C$4.50
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Misc:
  • Average Volume: 15,974 shs.
 
Frequently Asked Questions for IntelliPharmaCeutics International (TSE:I)

What is IntelliPharmaCeutics International's stock symbol?

IntelliPharmaCeutics International trades on the Tornton Stock Exchange (TSX) under the ticker symbol "I."

How were IntelliPharmaCeutics International's earnings last quarter?

IntelliPharmaCeutics International Inc. (TSE:I) issued its earnings results on Monday, April, 14th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.07. The company earned $5.14 million during the quarter, compared to analyst estimates of $3.63 million. View IntelliPharmaCeutics International's Earnings History.

Who are some of IntelliPharmaCeutics International's key competitors?

Who are IntelliPharmaCeutics International's key executives?

IntelliPharmaCeutics International's management team includes the folowing people:

  • Isa Odidi Ph.D., Chairman of the Board, Chief Executive Officer
  • Amina Odidi Ph.D., President, Chief Operating Officer, Director
  • Domenic Della Penna, Chief Financial Officer
  • John N. Allport, Vice President - Legal Affairs and Licensing, Secretary, Director
  • Patrick N. Yat Ph.D., Vice President - Pharmaceutical Analysis and Chemistry
  • Kenneth Keirstead, Independent Director
  • Bahadur Madhani, Independent Director
  • Eldon R. Smith M.D., Independent Director

How do I buy IntelliPharmaCeutics International stock?

Shares of IntelliPharmaCeutics International and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is IntelliPharmaCeutics International's stock price today?

One share of IntelliPharmaCeutics International stock can currently be purchased for approximately C$3.23.


MarketBeat Community Rating for IntelliPharmaCeutics International (TSE I)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  9 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  17
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for IntelliPharmaCeutics International (TSE:I) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for IntelliPharmaCeutics International (TSE:I)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for IntelliPharmaCeutics International (TSE:I)
Earnings by Quarter for IntelliPharmaCeutics International (TSE:I)
Earnings History by Quarter for IntelliPharmaCeutics International (TSE I)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/14/2014$0.03$0.10$3.63 million$5.14 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for IntelliPharmaCeutics International (TSE:I)
Current Year EPS Consensus Estimate: $0.23 EPS

Dividends

Dividend History for IntelliPharmaCeutics International (TSE:I)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for IntelliPharmaCeutics International (TSE:I)
Insider Trades by Quarter for IntelliPharmaCeutics International (TSE:I)
Insider Trades by Quarter for IntelliPharmaCeutics International (TSE:I)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2015Penna Domenic DellaInsiderBuy3,510C$2.10C$7,371.00
11/25/2015Penna Domenic DellaInsiderBuy20,375C$1.87C$38,101.25
10/29/2015Bahadur MadhaniDirectorBuy1,000C$2.42C$2,420.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for IntelliPharmaCeutics International (TSE:I)
Latest Headlines for IntelliPharmaCeutics International (TSE:I)
Source:
DateHeadline
rttnews.com logoEagle's Wings Clipped, FDA Panel Snubs IPCI, No Respite For CUR, MDXG On Watch
www.rttnews.com - July 27 at 2:13 AM
globenewswire.com logoIntellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended release), an ...
globenewswire.com - July 27 at 2:13 AM
nasdaq.com logoIntellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride ... - Nasdaq
www.nasdaq.com - July 26 at 9:11 PM
thestreet.com logoCanadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid - TheStreet.com
www.thestreet.com - July 25 at 8:00 PM
seekingalpha.com logoIntelliPharmaCeutics International - Very Low Downside And Huge Upside - Seeking Alpha
seekingalpha.com - July 25 at 8:00 PM
cnbc.com logoUPDATE 1-FDA staff raise concerns about Intellipharma's opioid painkiller
www.cnbc.com - July 25 at 4:20 AM
reuters.com logoFDA staff raise concerns about Intellipharma's opioid painkiller - Reuters
www.reuters.com - July 24 at 11:17 PM
cnbc.com logoIntellipharmaceutics reports 2Q loss
www.cnbc.com - July 11 at 11:25 PM
nasdaq.com logoIntellipharmaceutics Announces Second Quarter 2017 Results
www.nasdaq.com - July 11 at 11:25 PM
zacks.com logoIntellipharmaceutics International (IPCI) Jumps: Stock Up 19%
www.zacks.com - July 5 at 8:10 AM
streetinsider.com logoIntellipharmaceutics (IPCI) Reports FDA Advisory Committee Meeting for Rexista to Review NDA on 7/26
www.streetinsider.com - June 30 at 7:50 PM
globenewswire.com logoIntellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent ...
globenewswire.com - June 30 at 7:50 PM
reuters.com logoBRIEF-Intellipharmaceutics announces FDA advisory committee meeting for rexista
www.reuters.com - June 30 at 7:50 PM
reuters.com logoBRIEF-Intellipharmaceutics announces launch of generic seroquel XR by Mallinckrodt
www.reuters.com - June 6 at 6:21 PM
globenewswire.com logoIntellipharmaceutics Announces Launch of Generic Seroquel XR® by Mallinckrodt - GlobeNewswire (press release)
globenewswire.com - June 6 at 10:42 AM
reuters.com logoBRIEF-Intellipharmaceutics International files for mixed shelf offering of up to $100 mln
www.reuters.com - May 27 at 4:33 AM
globenewswire.com logoIntellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical - GlobeNewswire (press release)
globenewswire.com - May 24 at 5:41 PM
globenewswire.com logoIntellipharmaceutics Reports Director Election Results - GlobeNewswire (press release)
globenewswire.com - April 19 at 11:31 AM
zacks.com logoIntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected
www.zacks.com - April 13 at 10:23 AM
reuters.com logoBRIEF-Intellipharmaceutics announces patent litigation by Purdue against its Rexista abuse-deterrent extended-release Oxycodone
www.reuters.com - April 10 at 5:32 PM
finance.yahoo.com logoIntellipharmaceutics Announces TSX Trading Symbol Change to “IPCI”
finance.yahoo.com - March 16 at 4:27 PM
reuters.com logoBRIEF-Intellipharmaceutics announces FDA approval for 500 mg and 750 mg generic Glucophage XR
www.reuters.com - February 25 at 12:06 AM
finance.yahoo.com logoIntellipharmaceutics Announces 2016 Year End Results
finance.yahoo.com - February 10 at 6:32 PM
biz.yahoo.com logoQ4 2016 IntelliPharmaCeutics International Inc Earnings Release - 4:00 pm ET
biz.yahoo.com - February 7 at 7:05 PM
finance.yahoo.com logoIntellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
finance.yahoo.com - February 2 at 6:30 PM
finance.yahoo.com logoIntellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical - Yahoo Finance
finance.yahoo.com - January 8 at 5:44 AM
globenewswire.com logoIntellipharmaceutics to Present at the Biotech Showcase™ - GlobeNewswire (press release)
globenewswire.com - December 29 at 5:52 PM
seekingalpha.com logoIntellipharmaceutics awarded patents covering PODRAS technology - Seeking Alpha
seekingalpha.com - December 23 at 4:05 AM

Social

Chart

IntelliPharmaCeutics International (I) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff